We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Hinge Health raised its 2026 revenue guidance to $856-$860M after second-quarter revenues jumped 53%.
Migraine Care reached 450 clients and 5M eligible lives, while GI expansion adds nearly 100 clients.
HNGE's product investments and $105M Cylinder Health integration could temper the pace of margin expansion.
Hinge Health (HNGE - Free Report) is well-positioned for sustained growth, driven by robust revenue growth, expanding opportunities in Migraine and gastrointestinal (GI) care and a scalable AI-powered MSK platform. The raised 2026 outlook, broader enterprise reach and growing sales pipeline further support the growth outlook. However, continued investments and Cylinder Health integration could weigh on margin expansion.
This Zacks Rank #3 (Hold) company’s shares have surged 104.9% in the year-to-date period compared with 13.5% growth of the industry. The S&P 500 Composite has increased 11.5% during the said time frame.
The digital MSK care provider has a market capitalization of $7.66 billion. The company anticipates 30.6% growth for the next year and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 18.4%.
Image Source: Zacks Investment Research
Reasons Favoring HNGE’s Growth
Expanding Beyond Core MSK: Hinge Health is broadening its addressable market by applying its technology and distribution network to Migraine and GI care, with opportunities estimated at $78 billion and $135 billion, respectively. Migraine adoption surged to more than 450 clients covering over 5 million eligible lives in the second quarter.
Hinge Health is also acquiring Cylinder Health for $105 million to accelerate its GI expansion, adding nearly 100 clients across 2 million lives. The deal is expected to contribute $7-$8 million in 2026 revenues, with a broader rollout planned for 2027, creating additional wallet-share opportunities across Hinge Health’s existing client base.
Guidance Raise Reinforces Growth Outlook: Hinge Health’s second-quarter 2026 revenues jumped 53% year over year to $212.8 million, while LTM calculated billings rose 52% to $862 million, aided by stronger yields. Management raised 2026 revenue guidance to $856-$860 million and non-GAAP operating income guidance to $236-$244 million, implying a 28% margin at the midpoint. Third-quarter revenues are projected to be in the range of $223-$225 million, reflecting 45% growth at the midpoint and underscoring the improving contribution from enrolment, referrals and renewals.
Strong Q2 Results: Hinge Health delivered a strong second-quarter 2026 performance, supported by higher member yield, robust billings growth, margin expansion and a growing client base. Product expansion remains a key growth driver, with Migraine Care reaching more than 450 clients and 5 million lives, while the $105 million Cylinder Health acquisition expands HNGE into GI care. Improving win rates, a healthy sales pipeline and broader health-plan distribution further strengthen its land-and-expand strategy and support sustained growth.
A Factor That May Offset HNGE’s Gains
Reinvestment and Integration Can Temper Operating Leverage:Hinge Health continues to fund product expansion even as margins rise. Second-quarter 2026 GAAP operating expenses were $143.5 million, including $81.4 million of sales and marketing and $34.1 million of R&D. The planned $105 million Cylinder Health acquisition adds integration work, and management has said that GI will require investment before a broader 2027 rollout. Cylinder is expected to contribute only $7-$8 million of 2026 revenues after closing. Although full-year non-GAAP operating margin guidance increased to 28% at the midpoint, a faster build-out of GI, Migraine or other programs could reduce the pace of margin expansion.
Estimate Trend
Hinge Health is witnessing a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved south by 8 cents to $2.38.
The Zacks Consensus Estimate for third-quarter 2026 revenues is pegged at $225.2 million, indicating a 46.1% improvement from the year-ago quarter’s reported number. The consensus mark for third-quarter EPS is pegged at 63 cents, implying an 85.3% improvement year over year.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
Key Takeaways
Hinge Health (HNGE - Free Report) is well-positioned for sustained growth, driven by robust revenue growth, expanding opportunities in Migraine and gastrointestinal (GI) care and a scalable AI-powered MSK platform. The raised 2026 outlook, broader enterprise reach and growing sales pipeline further support the growth outlook. However, continued investments and Cylinder Health integration could weigh on margin expansion.
This Zacks Rank #3 (Hold) company’s shares have surged 104.9% in the year-to-date period compared with 13.5% growth of the industry. The S&P 500 Composite has increased 11.5% during the said time frame.
The digital MSK care provider has a market capitalization of $7.66 billion. The company anticipates 30.6% growth for the next year and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 18.4%.
Image Source: Zacks Investment Research
Reasons Favoring HNGE’s Growth
Expanding Beyond Core MSK: Hinge Health is broadening its addressable market by applying its technology and distribution network to Migraine and GI care, with opportunities estimated at $78 billion and $135 billion, respectively. Migraine adoption surged to more than 450 clients covering over 5 million eligible lives in the second quarter.
Hinge Health is also acquiring Cylinder Health for $105 million to accelerate its GI expansion, adding nearly 100 clients across 2 million lives. The deal is expected to contribute $7-$8 million in 2026 revenues, with a broader rollout planned for 2027, creating additional wallet-share opportunities across Hinge Health’s existing client base.
Guidance Raise Reinforces Growth Outlook: Hinge Health’s second-quarter 2026 revenues jumped 53% year over year to $212.8 million, while LTM calculated billings rose 52% to $862 million, aided by stronger yields. Management raised 2026 revenue guidance to $856-$860 million and non-GAAP operating income guidance to $236-$244 million, implying a 28% margin at the midpoint. Third-quarter revenues are projected to be in the range of $223-$225 million, reflecting 45% growth at the midpoint and underscoring the improving contribution from enrolment, referrals and renewals.
Strong Q2 Results: Hinge Health delivered a strong second-quarter 2026 performance, supported by higher member yield, robust billings growth, margin expansion and a growing client base. Product expansion remains a key growth driver, with Migraine Care reaching more than 450 clients and 5 million lives, while the $105 million Cylinder Health acquisition expands HNGE into GI care. Improving win rates, a healthy sales pipeline and broader health-plan distribution further strengthen its land-and-expand strategy and support sustained growth.
A Factor That May Offset HNGE’s Gains
Reinvestment and Integration Can Temper Operating Leverage:Hinge Health continues to fund product expansion even as margins rise. Second-quarter 2026 GAAP operating expenses were $143.5 million, including $81.4 million of sales and marketing and $34.1 million of R&D. The planned $105 million Cylinder Health acquisition adds integration work, and management has said that GI will require investment before a broader 2027 rollout. Cylinder is expected to contribute only $7-$8 million of 2026 revenues after closing. Although full-year non-GAAP operating margin guidance increased to 28% at the midpoint, a faster build-out of GI, Migraine or other programs could reduce the pace of margin expansion.
Estimate Trend
Hinge Health is witnessing a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved south by 8 cents to $2.38.
The Zacks Consensus Estimate for third-quarter 2026 revenues is pegged at $225.2 million, indicating a 46.1% improvement from the year-ago quarter’s reported number. The consensus mark for third-quarter EPS is pegged at 63 cents, implying an 85.3% improvement year over year.
Key Picks
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.